MedTrace Logo

13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

NCT02034877 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2016-07-01

Study results available
· View outcomes & findings →

Summary

This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65 years of age and in Indian children 6 to 17 years of age.

Conditions

  • Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

Interventions

BIOLOGICAL

13-valent Pneumococcal conjugate vaccine

1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1

PROCEDURE

Blood sample collection

10 mL of blood will be collected just before and approximately 1 month after vaccination.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
PREVENTION
Masking
NONE

Eligibility

Min Age
6 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02034877 on ClinicalTrials.gov